With experience working across more than 50 rare diseases, we are highly skilled in delivering clear and compelling healthcare communications in this complex and unique area, including:
Established in 2013, Comradis® is a specialist healthcare communications and commercialization consultancy that works exclusively on rare diseases, uncommon cancers and orphan drugs
people, not statistics
Our goal is to understand the needs of the rare disease community and look beyond the data to provide meaningful content
To secure a better future for families affected by rare diseases and uncommon cancers, we develop partnerships with pharmaceutical and biotechnology clients, patients, caregivers, advocates and clinicians
Congresses and educational meetings
Scientific communication platforms and messaging development
Publication planning and delivery
Patient engagement activities
Omni- and multichannel strategies, digital tools and resources
Advisory boards and insights gathering
Internal training activities
Medical and clinical trial educational resources
We provide objective analysis and creative programmes to make
novel treatments available earlier to more patients by:
Providing strategy planning and workshops
Identifying key experts and influencers
Understanding data gaps
Determining market size
Analysing reimbursement pathways and payer needs
Supporting product launch
We are active members of the rare disease community and understand the importance of collaboration between stakeholders to facilitate better outcomes for those living with rare diseases. To do this, we:
Participate in specialist rare disease congresses
Generate community-led publications
Contribute to community magazines
Collaborate with patient groups and charities
As experts in our field, we want to share our knowledge to stimulate conversation and inform viewpoints. Our latest white papers can be accessed below
For the 300 million people around the world who are living with a rare disease, they and their families face common challenges in their daily lives. The rarity of each individual disease means that people with rare diseases face difficulties in accessing health care and are more likely to experience misdiagnosis, lack of treatment and isolation.
This year, a key focus of Rare Disease Day on 28 February is equity – to recognize that everyone deserves equitable opportunities and access to health care. By working together, stakeholders in the community can help break down barriers and potentially change the landscape for the millions of people living with a rare disease.
Here at Comradis, we are passionate about health equity for the rare disease community and are supporting Rare Disease Day 2023.
In an exciting new study, researchers at Great Ormond Street Hospital in London have employed wearable motion tracking devices and artificial intelligence (AI) technology to estimate disease progression in patients with Duchenne muscular dystrophy (DMD). Clinical assessment of patients with neurological diseases often relies on subjective and qualitive endpoints that can be open to observer bias. This method, which utilized technology more commonly used to translate the movements of actors into life-like animated characters in films such as Avatar, captured patients’ whole-body movement behaviour to create a fuller picture of their disease, identifying patterns which would otherwise be undetectable by standard methods of assessment.
This technology has the potential to dramatically reduce time to diagnosis meaning that patients receive support and treatment quicker. Its applications may also extend to a clinical trial setting where it could be used to track response to new therapies, shorten the duration of trials and reduce the sample size required.
Here at Comradis, we are passionate about new technology and its potential applications in rare diseases such as DMD.
The 40th anniversary of the Orphan Drug Act represents a significant milestone for the rare disease community. In January 1983, the then-President of the United States of America, Ronald Reagan, signed the act into law, leading to significant advances in research, development, innovation, treatment and support for the rare disease community in the proceeding 40 years.
The National Organization for Rare Disorders (NORD) was formed in the same year as the Orphan Drug Act by the very advocates who lobbied for the act’s creation. As they also reach their 40th anniversary, it is important to acknowledge NORD’s momentous achievements in raising awareness of rare diseases and their ongoing support of the rare disease community.
As a medical communications agency focused on rare diseases, we celebrate these significant milestones and advocate the continued support of the rare disease community in the future.
We successfully collaborated with the Cure Sanfilippo Foundation and Sanfilippo Children's Foundation in publishing the first-ever global consensus clinical care guidelines for Sanfilippo syndrome (also known as mucopolysaccharidosis type III)
Establishing these clinical care guidelines means that anyone affected by Sanfilippo syndrome should receive the medical, rehabilitative and support care they need and deserve
A copy of the guidelines can be accessed here
Comradis® is part of AMICULUM®, an independent family of specialist healthcare communications agencies with over 350 medical communications professionals in 13 locations worldwide
Our team includes rare disease consultants, gene therapy communications experts, and experienced healthcare and patient advocacy professionals
We collaborate closely with colleagues from the wider family of AMICULUM® agencies, drawing expertise from other specialist teams
To learn more about how we can help you communicate and commercialize treatments for rare diseases and uncommon cancers, please get in touch